Case-Based Learning: Cancer-Associated Thrombosis During Noncytotoxic Therapy

Abstract

Cancer-associated thrombosis (CAT) remains a significant cause of morbidity and mortality among patients with malignancy, even during noncytotoxic therapy. With evolving therapeutic paradigms, understanding the mechanisms, risk factors, clinical presentation, diagnosis, and evidence-based management of CAT in the context of noncytotoxic treatments is critical for optimizing patient outcomes. This review synthesizes recent evidence, guidelines, and expert perspectives, providing a case-based, mechanism-driven overview for clinicians.

Introduction

Venous thromboembolism (VTE) is a well-recognized complication in patients with cancer, ranking as the second leading cause of death in this population. While cytotoxic chemotherapy is a well-established risk factor for VTE, the landscape of cancer therapy has expanded to include targeted agents, immunotherapies, hormonal therapies, and supportive care drugs. These noncytotoxic therapies can also modulate thrombotic risk, often via distinct mechanisms and patient-specific factors. This article reviews the epidemiology, mechanisms, risk factors, clinical features, diagnostic approach, management, and emerging therapies for CAT during noncytotoxic therapy, with reference to current guidelines and practical clinical insights.

Epidemiology / Disease Burden

The incidence of CAT varies widely, influenced by cancer type, stage, and treatment modality. Recent population-based studies estimate that up to 20% of all VTE cases occur in patients with malignancy. Importantly, even in the absence of cytotoxic chemotherapy, certain noncytotoxic agents including hormonal therapies (e.g., tamoxifen), antiangiogenic agents (e.g., bevacizumab), and immunotherapies have been implicated in elevated thrombotic risk. With improved cancer survival and longer exposure to such therapies, the cumulative burden of CAT in this patient population is rising, necessitating vigilant prevention, early detection, and effective management.

Pathophysiology

The pathogenesis of CAT is multifactorial, reflecting the interplay of Virchow's triad: endothelial injury, hypercoagulability, and venous stasis. Noncytotoxic agents may disrupt vascular integrity, alter pro- and anticoagulant protein expression, or induce inflammatory cascades. For example, antiangiogenic agents inhibit VEGF, impairing endothelial repair and promoting a prothrombotic milieu. Hormonal therapies may increase levels of clotting factors and reduce natural anticoagulants. Immunotherapies can trigger immune-mediated vascular injury and cytokine release. Furthermore, cancer itself produces procoagulant factors (e.g., tissue factor, cancer procoagulant), amplifying thrombotic risk.

Risk Factors

Risk stratification for CAT during noncytotoxic therapy requires careful consideration of patient-, tumor-, and treatment-specific variables. High-risk malignancies include pancreatic, gastric, brain, and lung cancers. Additional risk factors include advanced stage, previous VTE, immobilization, obesity, inherited thrombophilias, and the use of central venous catheters. Noncytotoxic therapies associated with increased CAT risk include selective estrogen receptor modulators, aromatase inhibitors, antiangiogenic agents, and immune checkpoint inhibitors. Clinical prediction models, such as the Khorana score, can aid in initial risk assessment, though their performance in the noncytotoxic setting may be variable.

Clinical Features

The clinical presentation of CAT ranges from asymptomatic, incidentally detected thrombosis to life-threatening pulmonary embolism. Symptoms and signs are often nonspecific and may overlap with cancer- or therapy-related side effects. Common presentations include unilateral limb swelling, pain, erythema, and dyspnea. Notably, atypical sites of thrombosis (e.g., splanchnic, cerebral veins) are more frequent in cancer patients. Clinicians should maintain a high index of suspicion, particularly in patients with new or unexplained symptoms during noncytotoxic therapy.

Diagnosis

Timely and accurate diagnosis of CAT is essential to reduce morbidity and mortality. Diagnostic workup typically includes clinical assessment, D-dimer testing (noting its limited specificity in cancer), and imaging studies such as compression ultrasonography for deep vein thrombosis or CT pulmonary angiography for suspected pulmonary embolism. Incidental findings on routine staging or surveillance imaging are increasingly recognized. Advanced imaging modalities, including MRI or PET-CT, may be warranted in select cases. Laboratory workup to evaluate for thrombophilia or coagulopathy may be considered in recurrent or atypical cases, though routine testing is not universally recommended.

Treatment & Management

Anticoagulation is the mainstay of CAT treatment. Low molecular weight heparin (LMWH) has historically been the preferred first-line therapy, owing to its efficacy and safety profile. Direct oral anticoagulants (DOACs), such as edoxaban, apixaban, and rivaroxaban, are now supported by randomized trials (e.g., Hokusai VTE Cancer, SELECT-D), demonstrating non-inferiority to LMWH for VTE recurrence and similar or slightly increased bleeding risk. The choice of anticoagulant must be individualized based on bleeding risk, drug-drug interactions, renal function, gastrointestinal involvement, and patient preference. Duration of anticoagulation is typically at least 3-6 months, with ongoing therapy often required for active cancer or continued exposure to prothrombotic therapies. Mechanical prophylaxis and inferior vena cava filters may be considered in select scenarios where anticoagulation is contraindicated.

Recent Advances / Emerging Therapies

Recent years have witnessed the integration of DOACs into CAT management, with emerging data on their use in various cancer subtypes and in combination with newer noncytotoxic agents. Ongoing trials are evaluating risk-adapted prophylaxis strategies, biomarker-driven approaches, and the safety of anticoagulation in patients with thrombocytopenia or high bleeding risk. Novel agents targeting upstream coagulation pathways (e.g., factor XI inhibitors) and immunomodulatory therapies are under investigation. The role of personalized medicine, leveraging patient-specific risk profiles and pharmacogenomics, is an evolving frontier in CAT care.

Guideline Recommendations

Current international guidelines (e.g., ASCO, NCCN, ISTH) recommend LMWH or DOACs as first-line therapy for CAT, with careful risk-benefit assessment in patients receiving noncytotoxic agents. Routine pharmacologic prophylaxis is not universally advised for all outpatients but may be considered in high-risk individuals, particularly those with elevated Khorana scores or high-risk tumor types. Regular reassessment of VTE and bleeding risk is emphasized, along with multidisciplinary collaboration among oncology, hematology, and pharmacy teams. Guidelines highlight the need for patient education, shared decision-making, and individualized care pathways.

Conclusion

Cancer-associated thrombosis remains a significant clinical challenge during noncytotoxic therapy, necessitating a nuanced understanding of evolving risk factors, mechanisms, and management strategies. Recent advances in anticoagulant therapy, risk stratification, and guideline recommendations have improved patient outcomes, yet ongoing research and multidisciplinary collaboration are essential. Optimizing CAT prevention and treatment in the era of noncytotoxic therapy requires integration of evidence-based practice, patient-centered care, and continued vigilance for thrombotic complications across the cancer care continuum.